UCB’s IL-17 latecomer bimekizumab beats Cosentyx in psoriasi...

Belgian biopharma company UCB is bringing up the rear of the IL-17 inhibitor category with its bimekizumab drug, so is celebrating new late-stage data showing superiority to th

Failed trial puts future of UCB’s epilepsy drug padsevonil i...

UCB’s James Musick on embracing digital therapeutics

Digital has rapidly taken over the pharma industry, but many still don’t fully understand how to harness it.

Janssen trials ultrasound-guided approach to treating Crohn'...

In the highly competitive market for inflammatory diseases such as Crohn's, pharma companies are looking for ways to maximise benefits of already approved drugs, as well as

UCB/Amgen's Evenity approved in Europe after appeal

UCB and Amgen’s osteoporosis drug Evenity has finally been approved in Europe, following a successful appeal against a regulatory rejection, to become the first new drug for the condition s

UCB posts more supportive data from Humira rival bimekizumab

There’s a whole gang of pharma companies queueing up to steal market share from AbbVie’s mega-blockbuster Humira, and UCB’s contender bimekizumab is shaping up for a challenge with another